Status: Recruiting
Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
This study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of Irinotecan Drug-Eluting Beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer liver metastases. The study is planned to enrolled 126 patients failing first- and second-line standard chemotherapy treatment.
Participants needed: 126
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: May 15, 2023Locations: 1
Eligibility criteria
Patients over 18 years of age, of any race or sex, who have histologic or radiol... [+12]
Prior treatment with TACE, regorafenib or fruquintinib [+7]